Can vitamin a derivative revive immune therapy for breast cancer?

This study tests whether adding retinoic acid (a vitamin A derivative) to an immune checkpoint inhibitor can help shrink tumors or slow disease progression in people with HER2-negative breast cancer whose cancer stopped responding to prior immunotherapy. About 10 participants will receive the combination treatment. The goal is to see if this approach can restore the immune system's ability to fight the cancer.